Avanos Medical Inc
$ 24.62
-0.16%
17 Apr - close price
- Market Cap 1,149,118,000 USD
- Current Price $ 24.62
- High / Low $ 24.65 / 24.61
- Stock P/E N/A
- Book Value 16.75
- EPS -1.57
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE -0.09 %
- 52 Week High 24.72
- 52 Week Low 9.30
About
Avanos Medical, Inc. is a medical technology company focused on providing medical device solutions to improve the quality of life for patients in North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America. The company is headquartered in Alpharetta, Georgia.
Analyst Target Price
$14.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-05 | 2025-07-29 | 2025-04-30 | 2025-02-18 | 2024-10-30 | 2024-07-31 | 2024-05-02 | 2024-02-20 | 2023-11-01 | 2023-08-09 | 2023-05-03 |
| Reported EPS | 0.29 | 0.22 | 0.17 | 0.1413 | 0.43 | 0.36 | 0.29 | 0.19 | 0.32 | 0.42 | 0.37 | 0.27 |
| Estimated EPS | 0.25 | 0.18 | 0.15 | 0.18 | 0.3967 | 0.35 | 0.29 | 0.21 | 0.37 | 0.28 | 0.3 | 0.27 |
| Surprise | 0.04 | 0.04 | 0.02 | -0.0387 | 0.0333 | 0.01 | 0 | -0.02 | -0.05 | 0.14 | 0.07 | 0 |
| Surprise Percentage | 16% | 22.2222% | 13.3333% | -21.5% | 8.3943% | 2.8571% | 0% | -9.5238% | -13.5135% | 50% | 23.3333% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.23 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AVNS
2026-04-19 04:10:02
Google's 2026 Discover Core Update significantly alters how investors access information on stocks like Avanos Medical Inc (NYSE: AVNS) by prioritizing personalized, mobile-first delivery of financial news directly to the Google app feed. This shift means faster access to critical updates—such as product launches or regulatory changes—without needing to search, offering a potential edge in the fast-paced healthcare sector. For investors, enabling Web & App Activity and following AVNS-related queries will enhance personalization, allowing for timely insights on market dynamics and strategic developments.
2026-04-18 05:08:39
Wall Street Zen downgraded Avanos Medical (NYSE:AVNS) from "buy" to "hold," contributing to a consensus "Reduce" rating on MarketBeat. Despite beating Q4 earnings and revenue estimates, the company's FY2026 EPS guidance fell below sell-side expectations, impacting analyst sentiment. Institutional ownership remains very high at 95.17%, with significant increases in positions from major funds like Northwestern Mutual Wealth Management Co.
2026-04-17 11:39:18
This article identifies two healthcare stocks, Avanos Medical (AVNS) and Revolution Medicines (RVMD), that are currently considered overbought based on their Relative Strength Index (RSI) values. Avanos Medical recently agreed to an acquisition, causing its stock to surge, while Revolution Medicines priced significant share and convertible note offerings. Both companies have experienced substantial gains over the past five days, leading to high RSI values indicating potential for a short-term pullback.
2026-04-16 16:09:21
Avanos Medical is set to be acquired by affiliates of American Industrial Partners (AIP) in an all-cash deal valued at $1.272 billion. Stockholders will receive $25 per share, a 72.1% premium over the closing price on April 13, 2026. This acquisition will take Avanos private, granting it enhanced flexibility and resources for long-term growth and innovation.
2026-04-15 15:39:45
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Avanos Medical, Inc. (NYSE: AVNS) to affiliates of American Industrial Partners for an offer of $25.00 cash per share. KSF aims to determine if this consideration and the sale process are adequate or if the Company is undervalued. Shareholders are encouraged to contact KSF if they believe the transaction undervalues the company or wish to discuss their legal rights.
2026-04-15 14:39:45
American Industrial Partners (AIP) is set to acquire Avanos Medical in a $1.27 billion go-private deal, offering a 72.1% premium to its Monday closing stock price. Avanos, which generated $701.2 million in net sales last year, competes in specialty nutrition and pain management markets against major players. The acquisition is expected to provide Avanos with enhanced flexibility and resources to strengthen its competitive position and advance its innovation roadmap, aiming for $1 billion in revenue by 2030.
